Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Huapyong Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1790-0809; OpenAlex author ID A5052632851. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 14

  1. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Co-author DOI 10.1097/mpa.0000000000002606↗
  2. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  3. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  4. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  5. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  6. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-020-04051-x↗
  7. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  8. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  9. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. First author DOI 10.4251/wjgo.v12.i2.182↗
  10. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i11.421↗
  11. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. First author DOI 10.4251/wjgo.v10.i12.505↗
  12. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… First author DOI 10.1053/j.seminoncol.2018.01.001↗
  13. Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanc… Co-author DOI 10.1159/000375402↗
  14. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Co-author DOI 10.5009/gnl.2014.8.1.109↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moon Jae Chung · 13 shared papers, 2014–2024 · strength 1.28
  2. Seungmin Bang · 12 shared papers, 2014–2024 · strength 1.24
  3. Seung Woo Park · 11 shared papers, 2014–2024 · strength 1.16
  4. Jeong Youp Park · 11 shared papers, 2014–2024 · strength 1.16
  5. Jung Hyun Jo · 10 shared papers, 2017–2024 · strength 1.12
  6. Hee Seung Lee · 10 shared papers, 2017–2024 · strength 1.12
  7. Si Young Song · 11 shared papers, 2014–2022 · strength 1.02
  8. In Rae Cho · 4 shared papers, 2017–2026 · strength 0.56
  9. Mi‐Suk Park · 4 shared papers, 2017–2022 · strength 0.42
  10. Sang Hyub Lee · 2 shared papers, 2018–2026 · strength 0.37
  11. Jiyoung Keum · 2 shared papers, 2020–2024 · strength 0.29
  12. Jinwoo Ahn · 1 shared paper, 2026 · strength 0.29
  13. Woo Hyun Paik · 1 shared paper, 2026 · strength 0.29
  14. Muhan Yeo · 1 shared paper, 2026 · strength 0.29
  15. Jin Ho Choi · 1 shared paper, 2026 · strength 0.29
  16. Ji Kon Ryu · 1 shared paper, 2026 · strength 0.29
  17. Seung‐seob Kim · 2 shared papers, 2020–2022 · strength 0.25
  18. Ho Kyoung Hwang · 2 shared papers, 2020–2021 · strength 0.20
  19. Chang Moo Kang · 2 shared papers, 2020–2021 · strength 0.20
  20. Sang Hoon Lee · 1 shared paper, 2024 · strength 0.18
  21. Chan Su Park · 1 shared paper, 2024 · strength 0.18
  22. Jae Hee Cho · 1 shared paper, 2024 · strength 0.18
  23. Sung Ill Jang · 1 shared paper, 2024 · strength 0.18
  24. Kyung In Shin · 1 shared paper, 2024 · strength 0.18
  25. Seung‐Mo Hong · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.